Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidasezzxf in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma (NRG-GY026)
Document Type
Conference Proceeding
Publication Date
5-29-2024
Publication Title
Journal of Clinical Oncology
Abstract
Annual Meeting of the American Society of Clinical Oncology, 2024; May 21 - June 4, 2024; Chicago, IL
Volume
42
Issue
16
Recommended Citation
Erickson, Britt Kristina; Enserro, Danielle; Lankes, Heather A.; Dockery, Lauren E.; Ghamande, S.A.; Oliver, Matthew T.; Gressel, Gregory M.; Castellano, Tara; Ratner, Elena; Deery, Amy; Bishop, Erin; Bradford, Leslie Siriya; Pepin, Jessica Thomes; Burton, Elizabeth; Blank, Stephanie V.; Santin, Alessandro; Havrilesky, Laura J.; Aghajanian, Carol; Fader, Amanda Nickles; and Powell, Matthew A., "Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidasezzxf in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma (NRG-GY026)" (2024). School of Medicine Faculty Publications. 3106.
https://digitalscholar.lsuhsc.edu/som_facpubs/3106
10.1200/JCO.2024.42.16_suppl.TPS5641
Comments
TPS5641